Basic Information
INVOKANA
55154-1426
Regulatory Information
55154-1426
NDA204042
C73594
December 13, 2018
USA
These highlights do not include all the information needed to use INVOKANA safely and effectively. See full prescribing information for INVOKANA. INVOKANA (canagliflozin) tablets, for oral use Initial U.S. Approval: 2013
HUMAN PRESCRIPTION DRUG LABEL
9
Company Information
118546603
Active Ingredients
ANHYDROUS LACTOSE
Code: 3SY5LH9PMK
Class Code: IACT
MICROCRYSTALLINE CELLULOSE
Code: OP1R32D61U
Class Code: IACT
CROSCARMELLOSE SODIUM
Code: M28OL1HH48
Class Code: IACT
WATER
Code: 059QF0KO0R
Class Code: IACT
MAGNESIUM STEARATE
Code: 70097M6I30
Class Code: IACT
POLYVINYL ALCOHOL, UNSPECIFIED
Code: 532B59J990
Class Code: IACT
TITANIUM DIOXIDE
Code: 15FIX9V2JP
Class Code: IACT
POLYETHYLENE GLYCOL 3350
Code: G2M7P15E5P
Class Code: IACT
TALC
Code: 7SEV7J4R1U
Class Code: IACT
Hydroxypropyl Cellulose (1600000 WAMW)
Code: RFW2ET671P
Class Code: IACT
Active Moieties
canagliflozin anhydrous
Code: 6S49DGR869